Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma

Annals of Hepatology

Volumn 8, Issue 3, 2009, Pages 220-227

  Branco, Fernanda ^a,b,c   Brú, Concepció ^d   Vilana, Ramon ^d   Bianchi, Luis ^d   de Mattos, Angelo Alves ^e  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Santa Casa Complexo Hospitalar   (Brazil)

Author keywords

Dropout; Hepatocellular carcinoma; Liver transplantation; Percutaneous ethanol injection; Percutaneous treatment

Indexed keywords

ALCOHOL;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EXPLANT; FEMALE; FOLLOW UP; HEMOPERITONEUM; HOSPITAL ADMISSION; HUMAN; HYPERTRANSAMINASEMIA; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PERCUTANEOUS ETHANOL INJECTION; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; SURVIVAL RATE; TUMOR GROWTH; TUMOR NECROSIS; TUMOR RECURRENCE; TUMOR VOLUME; DRUG EFFECT; ECHOGRAPHY; INJECTION; LIVER; LIVER TUMOR; MIDDLE AGED; MORTALITY; NECROSIS; PATHOLOGY; PREOPERATIVE CARE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NECROSIS; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; WAITING LISTS;

EID: 77952481804     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31769-7     Document Type: Article

References (29)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19(3): 271-285.
2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-430.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42(5): 1208-1236.
4. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30(6): 1434-1440.
5. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Chris-tensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50(1): 123-128.
6. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129(1): 122-130.
7. Llovet JM, Castellano L, De Girolamo V, Di Santolo SS, Ma-rone A, Del Vecchio BC, et al. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology 2001; 34(3): 609-610.
8. Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T, et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 2008; 103(12): 3057-3062.
9. Moreno Planas JM, Lopez MJ, Gomez CA, Rubio GE, Perez AR, Boullosa GE, et al. Efficacy of hepatocellular carcinoma locoregional therapies on patients waiting for liver transplantation. Transplant Proc 2005; 37(3): 1484-1485.
10. Yao FY, Kinkhabwala M, Laberge JM, Bass NM, Brown R, Jr., Kerlan R, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005; 5(4 Pt 1): 795-804.
11. Fisher RA, Maluf D, Cotterell AH, Stravitz T, Wolfe L, Luketic V, et al. Non-resective ablation therapy for hepa-tocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004; 18(5): 502-512.
12. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, et al. Lack of benefit of pre-transplant lo-coregional hepatic therapy for hepatocellular cancer in the current meld era. Liver Transpl 2006; 12(4): 665-673.
13. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693-699.
14. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, et al. Percutaneous radiofrequency ablation of hepatocellu-lar carcinoma as a bridge to liver transplantation. Hepa-tology 2005; 41(5): 1130-1137.
15. Majno P, Giostra E, Morel P, Hadengue A, Mentha G. Management of hepatocellular carcinoma in the waiting list before liver transplantation. J Hepatol 2005; 42(Suppl. 1): S134-S143.
16. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228(1): 235-240.
17. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54(8): 1151-1156.
18. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008; 43(6): 727-735.
19. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatolo-gy 2004; 40(6): 1352-1360.
20. Taniguchi M, Kim SR, Imoto S, Ikawa H, Ando K, Mita K, et al. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol 2008; 14(13): 1997-2002.
21. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16(2): 353-357.
22. Castroagudin JF, Delgado M, Martinez SM, Abdulkader I, Potel J, Tome S, et al. Prospective histopathological analysis of hepatocellular carcinoma treated with percutaneous ethanol injection in patients on the waiting list for liver transplantation. Transplant Proc 2005; 37(3): 1477-1479.
23. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observation. J Hepatol 2005; 43(3): 458-464.
24. Ishii H, Okada S, Okusaka T, Yoshimori M, Nakasuka H, Shi-mada K, et al. Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1998; 82(9): 1638-1642.
25. Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation. Liver Transpl 2004; 10(10): 1294-1300.
26. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical ct for detection of hcc prior to liver transplantation: An explant correlation. Hepatology 2003; 38(4): 1034-1042.
27. Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl 2003; 9(7): 700-702.
28. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol 2009; 10(1): 35-43.
29. Llovet JM, Schwartz M, Fuster J, Bruix J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: Not yet there. Semin Liver Dis 2006; 26(3): 248-253.